Fatty liver and psoriasis study pulled before it started

NCT ID NCT07255781

Terminated Knowledge-focused Sponsor: University of California, San Diego Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study aimed to understand the link between non-alcoholic fatty liver disease (NAFLD) and psoriatic disease (psoriasis and psoriatic arthritis) in overweight adults. Researchers planned to use the drug guselkumab (Tremfya) to see if it improved both conditions. However, the trial was withdrawn before enrolling any participants, so no data or results are available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Guselkumab (Tremfya)

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PSORIASIS (PSO) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatotic liver disease pleomorphic adenoma psoriasis psoriatic arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NAFLD (NONALCOHOLIC FATTY LIVER DISEASE) PSA (PSORIATIC ARTHRITIS) PSORIASIS (PSO)

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••